Imunon (NASDAQ:IMNN) Posts Earnings Results, Beats Estimates By $0.38 EPS

Imunon (NASDAQ:IMNN) announced its quarterly earnings results on Tuesday. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.38, FiscalAI reports.

Here are the key takeaways from Imunon’s conference call:

• Imunon said OVATION 3 is progressing well, with management reiterating that enrollment remains on track and that the company expects to randomize about 80 patients by the end of Q1 2027.
• The company highlighted strong Phase II results for IMNN-001, including a 14.7-month median overall survival benefit in OVATION 2, which management believes supports the drug’s potential in frontline ovarian cancer.
• Management emphasized that the Phase III trial is designed around overall survival as the primary endpoint, with two planned interim analyses and a path that could support a single pivotal-trial BLA filing if successful.
• Imunon acknowledged the challenging biotech funding environment and said it is pursuing bridge financing and cost controls to extend runway while trying to minimize dilution.
• First-quarter 2026 operating cash use was $4.0 million, up from $2.8 million a year ago, largely due to OVATION 3 startup costs, while R&D and G&A expenses were roughly stable year over year.

Imunon Stock Performance

NASDAQ:IMNN traded down $0.09 during mid-day trading on Wednesday, reaching $2.61. 20,807 shares of the company’s stock were exchanged, compared to its average volume of 74,663. Imunon has a one year low of $2.52 and a one year high of $41.22. The business’s fifty day simple moving average is $2.98 and its two-hundred day simple moving average is $3.47. The firm has a market capitalization of $10.41 million, a PE ratio of -0.32 and a beta of 2.04.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Imunon stock. DRW Securities LLC increased its holdings in Imunon, Inc. (NASDAQ:IMNN) by 6.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,830 shares of the company’s stock after buying an additional 3,803 shares during the period. DRW Securities LLC owned 1.92% of Imunon worth $224,000 as of its most recent filing with the Securities and Exchange Commission. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a report on Tuesday, April 21st. Maxim Group set a $10.00 target price on Imunon and gave the company a “buy” rating in a research report on Friday, April 17th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Imunon presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.